NasdaqGM - Delayed Quote • USD
Concert Pharmaceuticals, Inc. (CNCE)
At close: April 4 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2022) | Next Qtr. (Mar 2023) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| No. of Analysts | 4 | 1 | 4 | 4 |
| Avg. Estimate | -0.63 | -0.87 | -2.76 | -2.69 |
| Low Estimate | -0.81 | -0.87 | -3 | -4.07 |
| High Estimate | -0.52 | -0.87 | -2.63 | -1.22 |
| Year Ago EPS | -1.01 | -1.03 | -2.33 | -2.76 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2022) | Next Qtr. (Mar 2023) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| No. of Analysts | 3 | 1 | 3 | 4 |
| Avg. Estimate | 110k | -- | 120k | 13.57M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | 340k | -- | 370k | 50M |
| Year Ago Sales | 13k | -- | 32.58M | 120k |
| Sales Growth (year/est) | 746.20% | -- | -99.60% | 11,208.30% |
Earnings History
| CURRENCY IN USD | 12/31/2021 | 3/31/2022 | 6/30/2022 | 9/30/2022 |
|---|---|---|---|---|
| EPS Est. | -0.73 | -0.91 | -0.85 | -0.59 |
| EPS Actual | -1.01 | -1.03 | -0.59 | -0.58 |
| Difference | -0.28 | -0.12 | 0.26 | 0.01 |
| Surprise % | -38.40% | -13.20% | 30.60% | 1.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Dec 2022) | Next Qtr. (Mar 2023) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| Current Estimate | -0.63 | -0.87 | -2.76 | -2.69 |
| 7 Days Ago | -0.63 | -0.87 | -2.76 | -2.69 |
| 30 Days Ago | -0.64 | -0.81 | -2.77 | -2.74 |
| 60 Days Ago | -0.64 | -0.81 | -2.77 | -2.7 |
| 90 Days Ago | -0.64 | -0.81 | -2.77 | -2.7 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Dec 2022) | Next Qtr. (Mar 2023) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | CNCE | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 37.60% | -- | -- | 1.60% |
| Next Qtr. | 15.50% | -- | -- | 10.50% |
| Current Year | -18.50% | -- | -- | 5.20% |
| Next Year | 2.50% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.22% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Related Tickers
DICE
CALA Calithera Biosciences, Inc.
0.0251
0.00%
CMPX Compass Therapeutics, Inc.
1.4700
-1.34%
DAWN Day One Biopharmaceuticals, Inc.
14.96
-5.02%
ANNX Annexon, Inc.
4.5600
+2.70%
RVMD Revolution Medicines, Inc.
34.92
-2.54%
CORT Corcept Therapeutics Incorporated
22.95
+1.28%
AVRO AVROBIO, Inc.
1.2000
-3.23%
MIRM Mirum Pharmaceuticals, Inc.
23.81
+1.02%
CLDX Celldex Therapeutics, Inc.
37.98
-1.43%